dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Lozano, Rebeca |
dc.contributor.author | Lorente, David |
dc.contributor.author | Aragon, Isabel M. |
dc.contributor.author | Romero-Laorden, Nuria |
dc.contributor.author | Nombela, Paz |
dc.contributor.author | Mateo Valderrama, Joaquim |
dc.date.accessioned | 2022-03-01T07:43:02Z |
dc.date.available | 2022-03-01T07:43:02Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Lozano R, Lorente D, Aragon IM, Romero-Laorden N, Nombela P, Mateo J, et al. Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients. Cancers (Basel). 2021 May;13(10):2334. |
dc.identifier.issn | 2468-0249 |
dc.identifier.uri | https://hdl.handle.net/11351/7102 |
dc.description | Biomarcadors; Cèl·lules tumorals circulants; Docetaxel |
dc.description.sponsorship | The results reported here were generated as part of two academic studies supported by various grants. The funding sources had no role in study design, data analysis, data interpretation or writing of the report. R.L., D.L. and D.O. had full access to all of the data and had final responsibility for the decision to submit for publication. This project represents independent research supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, London. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;13(10) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pròstata - Càncer - Tractament |
dc.subject | Cèl·lules canceroses - Proliferació |
dc.subject | Metàstasi |
dc.subject.mesh | Prostatic Neoplasms, Castration-Resistant |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Neoplastic Cells, Circulating |
dc.title | Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers13102334 |
dc.subject.decs | neoplasias prostáticas resistentes a la castración |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | células neoplásicas circulantes |
dc.relation.publishversion | https://doi.org/10.3390/cancers13102334 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Lozano R, Aragon IM] Genitourinary Cancer Traslational Research Group, The Institute of Biomedical Research in Málaga (IBIMA), 29010 Málaga, Spain. Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. [Lorente D] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. Servicio de Oncología Médica, Hospital Provincial de Castellón, 12004 Castellón de la Plana, Spain. [Romero-Laorden N] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. Hospital Universitario La Princesa, 28006 Madrid, Spain. [Nombela P] Spanish National Cancer Research Centre (CNIO), Prostate Cancer Clinical Research Unit, 28029 Madrid, Spain. [Mateo J] The Institute of Cancer Research, London SW7 3RP, UK. The Royal Marsden NHS Foundation Trust, Sutton, London SM2 5PT, UK. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34066080 |
dc.identifier.wos | 000696709200009 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |